Pulse nav.journalClub Aktive Debatten Trends Entdecken Forschende

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Start Entdecken nav.journalClub Trends

⌘+K

March 20, 2017

Orale direkt wirkende Wirkstofftherapie bei Hepatitis-C-Virus-Infektionen

Key Points

Key points are not available for this paper at this time.

Abstract

Patientenorientierte Ergebnisse Forschungsinstitut. (PROSPERO: CRD42014009711).

KI fragen

Like

Bookmark

Share

KI fragen

Like

Bookmark

Share

Cite This Study

Falade‐Nwulia et al. (Mon,) untersuchten diese Frage.

synapsesocial.com/papers/69dbe0e5498b35d3e6a3d6ef https://doi.org/https://doi.org/10.7326/m16-2575

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pharmaceutical industry sponsorship and research outcome and quality: systematic review2003 · 2,163 citations
2Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study2016 · 189 citations
3Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-12015 · 305 citations
4Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence2016 · 459 citations
5Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin2014 · 907 citations

Orale direkt wirkende Therapien bei Hepatitis-C-Virus-Infektionen | Synapse